FindTrial
Sign In

TAS6417

DRUG3 trials

Sponsors

Taiho Oncology, Inc.

Conditions

AdjuvantAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsAdvanced or Metastatic NSCLS With Exon 20 Insertion MutationEGFREarly Stage Lung CancerExon 20Lung CancerNSCLC, Early Stage

Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
RecruitingNCT05967689
Taiho Oncology, Inc.Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Start: 2023-07-31End: 2028-12-31Target: 220Updated: 2026-09-01

Phase 3

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Active, not recruitingNCT05973773
Taiho Oncology, Inc.Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Start: 2023-12-18End: 2027-05-27Updated: 2026-07-30
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Active, not recruitingNCT07128199
Taiho Oncology, Inc.Adjuvant, Early Stage Lung Cancer, EGFR +5
Start: 2025-12-22End: 2032-10-01Target: 360Updated: 2026-08-26

Related Papers

REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with <i>EGFR</i> exon 20 insertion-mutated NSCLC
Future Oncology2025-02-167 citations
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Journal of Clinical Oncology2025-01-2916 citations
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (<i>EGFR</i>) exon 20 insertions (ex20ins) mutations.
Journal of Clinical Oncology2024-08-102 citations
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (<i>EGFR</i>) exon 20 insertions (ex20ins) mutations.
Journal of Clinical Oncology2024-06-015 citations
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (<i>EGFR</i>) mutations.
Journal of Clinical Oncology2024-06-011 citations
Mobocertinib: Mechanism of action, clinical, and translational science
Clinical and Translational Science2024-03-0116 citations